The effects of 1992 on the pharmaceuticals industry in Britain and Germany

P E Hart ()

No 8, National Institute of Economic and Social Research (NIESR) Discussion Papers from National Institute of Economic and Social Research

Abstract: The completion of the Single European Market after 1992 is expected to intensify competition generally although different industries will be affected in different ways. The pharmaceuticals industry in Britain and Germany is one of four selected for closer examination. It is clear that effects of '1992' in the form of greater harmonization of drug regulations, more intensive merger and acquisition activity, and increased pressure on price‐cost margins are merely a subset of the many disturbances likely to affect firms in this industry. The agreed extension of effective patent life will help to improve the level and stability of economic performance but because the most valuable British drugs have more unexpired life than their German counterparts, it would appear that in this industry German firms are more vulnerable than British firms to '1992'.

Date: 1992-03
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.niesr.ac.uk/wp-content/uploads/1992/03/DP8.pdf

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nsr:niesrd:8

Access Statistics for this paper

More papers in National Institute of Economic and Social Research (NIESR) Discussion Papers from National Institute of Economic and Social Research 2 Dean Trench Street Smith Square London SW1P 3HE. Contact information at EDIRC.
Bibliographic data for series maintained by Library & Information Manager ().